Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | IL1B | P01584 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL951482 | 0.82 | GABRP (0.34) | KDM4EHSD17B10ALDH1A1ALOX15MAPT | |
| SCHEMBL949344 | 0.78 | CASP1 (0.60) | KDM4EALDH1A1CASP1IL1BPOLB | |
| SCHEMBL950152 | 0.75 | ELANE (0.57) | CASP1IL1BL3MBTL1 | |
| SCHEMBL950205 | 0.74 | ELANE (0.45) | KDM4EHSD17B10ALDH1A1ALOX15KMT2A | |
| SCHEMBL27473868 | 0.73 | GAA (0.40) | IDH1ALDH1A1CASP1IL1BKMT2A | |
| SCHEMBL4456640 | 0.73 | ALDH1A1 (0.44) | IDH1KDM4EHSD17B10ALDH1A1CASP1 | |
| SCHEMBL8402040 | 0.73 | KDM4E (0.38) | KDM4EALDH1A1KMT2AMEN1POLB | |
| SCHEMBL948599 | 0.73 | ALDH1A1 (0.41) | KDM4EHSD17B10ALDH1A1CASP1KMT2A | |
| SCHEMBL949769 | 0.73 | CASP1 (0.33) | IDH1CASP1IL1B | |
| SCHEMBL27501506 | 0.72 | CASP1 (0.42) | IDH1CASP1IL1BKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015371-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-20 | — | — | US | disclosed |
| US-7772366-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-7288624-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-30 | — | — | US | disclosed |
| EP-1394175-A1 | Inhibitors of interleukin-1beta converting enzyme | Vertex Pharmaceuticals Incorporated (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20020099042-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2002-07-25 | — | — | US | disclosed |
| US-6103711-A | INTERLEUKIN-1 MEDIATED DISEASES; ANTIINFLAMMATORY AND -CARCINOGENIC AGENTS; AUTOIMMUNE AND NEURODEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2000-08-15 | — | — | US | disclosed |
| US-5973111-A | NOVEL COMPOUNDS THAT ARE CAPABLE OF BINDING TO THE ACTIVE SITE OF INTERLEUKIN-1B-CONVERTING ENZYME (ICE) AND INHIBITING ACTIVITY OF THAT ENZYME; ADMINISTERING TO TREAT INFLAMMATORY, AUTOIMMUNE, AND NEURODEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS, INC. (US) | 1999-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | IDH1 1052/4885KDM4E 3226/4885HSD17B10 816/4885 |
| US-20020099042-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1RN | IDH1 1043/4885KDM4E 3334/4885HSD17B10 820/4885 |
| US-20110015371-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | IDH1 1052/4885KDM4E 3226/4885HSD17B10 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.